UPDATE: Goldman Sachs Resumes Coverage on Ventas with a Buy Rating on Favorable Fundamentals

In a report published by Goldman Sachs, analyst Andrew Rosivach resumed coverage on Ventas

with a Buy rating and 12-month $88 price target. Goldman Sachs reported that, “We are resuming coverage of Ventas (VTR) with a Buy rating, relative to our Attractive healthcare coverage view, and a 12-month price target of $88 (30% upside including dividends). Our model forecasts a sturdy 74% AFFO growth rate (1% above our coverage universe average). We believe VTR's 26% exposure to RIDEA senior housing, where supply-demand fundamentals are very favorable, should give the company the best internal growth outlook in the healthcare sector.” Shares of Ventas closed at $69.89 on Wednesday.